HOMEOBRAIN Homeoproteins as novel therapies for neurodegenerative diseases
- Coordinator
- Brainever, France
- Runs
- 1 November 2022 to 31 October 2024
- Status
- Finished
- EU funding
- €2.5m
- Total cost
- €5.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190105256
What the project is doing
In the project's own words, from its summary on CORDIS.
With the ageing of the population, neurodegenerative diseases will be a huge societal, health and economic problem. There are no effective solutions that can stop the progression of these devastating diseases. At BrainEver we are developing a groundbreaking platform to treat neurodegenerative diseases based on a family of transcription factors called Homeoproteins (HPs). Homeoproteins are endogenous proteins expressed in diverse neuronal types, where they regulate age-dependent mechanisms related to neurodegeneration.
When homeoproteins are injected into the central nervous system of animals with disease, neuronal survival and function is restored, halting degeneration. This suggests a huge potential as therapies for neurodegenerative diseases. In this project, we aim to develop and clinically validate a revolutionary therapy using the homeoprotein Engrailed-1, to treat patients with Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease (PD).
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Brainever | Paris | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI